Celcuity
BiotechnologyView the employees at
Celcuity-
Ann De La Forest, PhD Scientist
-
Rising Star
Anders Persson Senior Principal Investigator at Celcuity-
Minneapolis, Minnesota, United States
-
Top 10%
Adrish Sen A virologist probing cancer cell vulnerabilities across the hierarchical continuum of the tumor (immune) environment!-
Minneapolis, Minnesota, United States
-
Top 5%
Nicole Osterhaus Quality Assurance Consultant-
St Paul, Minnesota, United States
-
Rising Star
Mar Reyes Clinical Data Management professional with over 25 years of industry experience-
Chula Vista, California, United States
-
Top 10%
Overview
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company’s lead therapeutic candidate is gedatolisib, a potent, reversible dual inhibitor that selectively targets all Class I isoforms of PI3K and mTOR. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. The company expects to initiate a Phase 3 study evaluating gedatolisib in patients with HR+/HER2- advanced breast cancer in 2022. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com
-